JP2017512304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512304A5 JP2017512304A5 JP2016550561A JP2016550561A JP2017512304A5 JP 2017512304 A5 JP2017512304 A5 JP 2017512304A5 JP 2016550561 A JP2016550561 A JP 2016550561A JP 2016550561 A JP2016550561 A JP 2016550561A JP 2017512304 A5 JP2017512304 A5 JP 2017512304A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarker
- pair
- immune system
- determining
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims description 672
- 108090000623 proteins and genes Proteins 0.000 claims description 265
- 108091033319 polynucleotide Proteins 0.000 claims description 216
- 102000040430 polynucleotide Human genes 0.000 claims description 216
- 239000002157 polynucleotide Substances 0.000 claims description 216
- 238000000034 method Methods 0.000 claims description 179
- 239000000523 sample Substances 0.000 claims description 99
- 230000003321 amplification Effects 0.000 claims description 71
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 71
- 239000003153 chemical reaction reagent Substances 0.000 claims description 47
- 101150019421 PLA2G7 gene Proteins 0.000 claims description 16
- 101150040780 PLAC8 gene Proteins 0.000 claims description 16
- 230000001747 exhibiting effect Effects 0.000 claims description 16
- 238000011002 quantification Methods 0.000 claims description 15
- 238000012545 processing Methods 0.000 claims description 13
- 238000009826 distribution Methods 0.000 claims description 12
- 101150087010 CEACAM4 gene Proteins 0.000 claims description 11
- 101150048357 Lamp1 gene Proteins 0.000 claims description 11
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 102100025472 Carcinoembryonic antigen-related cell adhesion molecule 4 Human genes 0.000 claims description 8
- 101000914325 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 4 Proteins 0.000 claims description 8
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 claims description 8
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims description 5
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 238000003753 real-time PCR Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 description 398
- 108020004999 messenger RNA Proteins 0.000 description 52
- 229920001184 polypeptide Polymers 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 102000004196 processed proteins & peptides Human genes 0.000 description 32
- 206010040047 Sepsis Diseases 0.000 description 25
- 206010040070 Septic Shock Diseases 0.000 description 14
- 230000036303 septic shock Effects 0.000 description 14
- 239000003550 marker Substances 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000004393 prognosis Methods 0.000 description 9
- 238000010839 reverse transcription Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 4
- 102100022898 Galactoside-binding soluble lectin 13 Human genes 0.000 description 3
- 101000620927 Homo sapiens Galactoside-binding soluble lectin 13 Proteins 0.000 description 3
- 101000691480 Homo sapiens Placenta-specific gene 8 protein Proteins 0.000 description 3
- 101001097889 Homo sapiens Platelet-activating factor acetylhydrolase Proteins 0.000 description 3
- 102100037518 Platelet-activating factor acetylhydrolase Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003062 neural network model Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014900363A AU2014900363A0 (en) | 2014-02-06 | Biomarker Signature Method, and Apparatus and Kits Therefor | |
| AU2014900363 | 2014-02-06 | ||
| PCT/AU2015/050043 WO2015117204A1 (en) | 2014-02-06 | 2015-02-06 | Biomarker signature method, and apparatus and kits therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512304A JP2017512304A (ja) | 2017-05-18 |
| JP2017512304A5 true JP2017512304A5 (https=) | 2018-04-19 |
Family
ID=53754326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550561A Pending JP2017512304A (ja) | 2014-02-06 | 2015-02-06 | バイオマーカーシグネチャー法ならびにそのための装置およびキット |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11047010B2 (https=) |
| EP (1) | EP3103046B1 (https=) |
| JP (1) | JP2017512304A (https=) |
| CN (1) | CN105981026A (https=) |
| AU (1) | AU2015213486B2 (https=) |
| CA (1) | CA2930925A1 (https=) |
| DK (1) | DK3103046T3 (https=) |
| WO (1) | WO2015117204A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10190169B2 (en) | 2013-06-20 | 2019-01-29 | Immunexpress Pty Ltd | Biomarker identification |
| US11047010B2 (en) | 2014-02-06 | 2021-06-29 | Immunexpress Pty Ltd | Biomarker signature method, and apparatus and kits thereof |
| AU2016267392B2 (en) * | 2015-05-28 | 2021-12-09 | Immunexpress Pty Ltd | Validating biomarker measurement |
| CN108513586A (zh) * | 2015-09-30 | 2018-09-07 | 因姆内克斯普雷斯私人有限公司 | 病原体生物标志物及其用途 |
| EP3371324B1 (en) * | 2015-11-06 | 2021-08-18 | ImmuneXpress Pty Ltd | Viral biomarkers and uses therefor |
| CN106701900B (zh) * | 2015-11-16 | 2020-03-20 | 上海市东方医院 | 长链非编码rna herc2p3基因及其在胃癌中的用途 |
| CN105256063B (zh) * | 2015-12-01 | 2019-03-01 | 北京泱深生物信息技术有限公司 | 肿瘤标志物dmbx1及其应用 |
| AU2016377391B2 (en) | 2015-12-24 | 2022-09-01 | Immunexpress Pty Ltd | Triage biomarkers and uses therefor |
| CN105506172B (zh) * | 2016-03-01 | 2019-04-09 | 北京泱深生物信息技术有限公司 | 含检测gfod2的骨质疏松血液诊断试剂及其应用 |
| US20230187067A1 (en) * | 2016-03-23 | 2023-06-15 | Peach Intellihealth, Inc. | Use of clinical parameters for the prediction of sirs |
| AU2017315328A1 (en) * | 2016-08-24 | 2019-03-21 | Immunexpress Pty Ltd | Systemic inflammatory and pathogen biomarkers and uses therefor |
| GB201616557D0 (en) * | 2016-09-29 | 2016-11-16 | Secretary Of State For Health The | Assay for distinguishing between sepsis and systemic inflammatory response syndrome |
| JP7274748B2 (ja) | 2016-11-08 | 2023-05-17 | クヴェッラ コーポレーション | 核酸の安定化及び分離を行う方法 |
| CN106755343A (zh) * | 2016-12-01 | 2017-05-31 | 北京致成生物医学科技有限公司 | 胰腺癌预后诊断分子标记物 |
| US11435370B2 (en) * | 2017-01-16 | 2022-09-06 | Shimadzu Corporation | Data analying device and program for data analysis |
| WO2018140256A1 (en) * | 2017-01-17 | 2018-08-02 | Duke University | Gene expression signatures useful to predict or diagnose sepsis and methods of using the same |
| CN108341862B (zh) * | 2017-01-24 | 2021-04-02 | 上海交通大学医学院附属仁济医院 | 一种多肽及其应用 |
| CN106947808B (zh) * | 2017-03-10 | 2020-07-24 | 北京赛尔得生物技术有限公司 | Tmem104基因在制备治疗椎间盘退行性疾病药物中的应用 |
| CN107133475B (zh) * | 2017-05-10 | 2020-09-29 | 浙江省立同德医院 | 一种中药注射剂不良反应高危患者模式识别方法 |
| EP3879535B1 (en) | 2017-06-13 | 2024-12-11 | BostonGene Corporation | Systems and methods for identifying cancer treatments from normalized biomarker scores |
| WO2019095064A1 (en) * | 2017-11-15 | 2019-05-23 | UNIVERSITé LAVAL | Use of srsf3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections |
| CN108467890A (zh) * | 2018-05-02 | 2018-08-31 | 首都医科大学附属北京天坛医院 | Vat1基因及vat1基因的干扰物的应用和应用vat1基因的产品 |
| CN108753834B (zh) * | 2018-05-28 | 2021-11-23 | 上海海洋大学 | ddx27基因缺失斑马鱼突变体的制备方法 |
| WO2020096984A1 (en) * | 2018-11-05 | 2020-05-14 | Institute For Systems Biology | Sepsis biomarker panels and methods of use |
| AU2019380342A1 (en) * | 2018-11-15 | 2021-07-01 | Ampel Biosolutions, Llc | Machine learning disease prediction and treatment prioritization |
| WO2020132327A1 (en) * | 2018-12-19 | 2020-06-25 | The Trustees Of The University Of Pennsylvania | Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias |
| CN111443065A (zh) * | 2019-01-17 | 2020-07-24 | 四川大学华西医院 | 一种肺癌的筛查试剂盒 |
| CN109762911B (zh) * | 2019-02-21 | 2020-12-01 | 华中农业大学 | Ptprj基因作为猪免疫相关性状的分子标记及其应用 |
| US12288623B2 (en) | 2019-03-19 | 2025-04-29 | Optina Diagnostics, Inc. | Method and system for identifying subjects who are potentially impacted by a medical condition |
| CN112409376A (zh) * | 2019-08-20 | 2021-02-26 | 华东师范大学 | 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用 |
| CN110567861B (zh) * | 2019-09-09 | 2021-12-21 | 浙江普罗亭健康科技有限公司 | 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法 |
| CN110558279B (zh) * | 2019-09-16 | 2021-11-16 | 南方科技大学 | 一种药物筛选模型、药物筛选方法及其应用 |
| CN110687285B (zh) * | 2019-10-29 | 2023-03-21 | 安徽医科大学 | 诊断试剂盒及mak16在制备系统性红斑狼疮早期诊断试剂中的应用 |
| CN110791523B (zh) * | 2019-12-13 | 2022-05-10 | 南京农业大学 | 一种棉花抗旱相关基因GhRCHY1及其应用 |
| CN111276248B (zh) * | 2020-01-20 | 2023-09-12 | 苏州帕诺米克生物医药科技有限公司 | 状态确定系统和电子设备 |
| CN114317746B (zh) * | 2020-03-30 | 2022-09-23 | 中国医学科学院肿瘤医院 | 外泌体arpc5、ypel2等在肺癌诊断中的应用 |
| CA3178405A1 (en) | 2020-05-14 | 2021-11-18 | Katherine A. OWEN | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus |
| CN114487402A (zh) * | 2020-11-12 | 2022-05-13 | 首都医科大学附属北京世纪坛医院 | 尿液非分泌核糖核酸酶蛋白及其多肽片段在妊娠糖尿病中的应用 |
| CN112553322B (zh) * | 2020-12-25 | 2022-07-05 | 深圳市人民医院 | 一种骨质疏松诊断标志物及其应用 |
| CA3211700A1 (en) * | 2021-02-11 | 2022-08-18 | Herbert A. Fritsche | Kits and methods for detecting markers and determining the presence or risk of cancer |
| CN113125757B (zh) * | 2021-04-22 | 2022-10-28 | 石河子大学 | 一种用于母猪早期妊娠诊断的蛋白生物标志物及其用于母猪早期妊娠检测的方法 |
| WO2022226267A1 (en) * | 2021-04-23 | 2022-10-27 | Alnylam Pharmaceuticals, Inc. | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN |
| AU2022283025A1 (en) * | 2021-05-25 | 2024-01-18 | The University Of British Columbia | Diagnostic for sepsis endotypes and/or severity |
| WO2023034111A1 (en) * | 2021-08-30 | 2023-03-09 | Inflammatix, Inc. | A baseline gene expression-based prognostic for anti-tnf alpha therapy response in patients with inflammatory bowel disease |
| AU2022375208B2 (en) * | 2021-10-29 | 2024-06-06 | GenoDx Pty Ltd | Biomarkers and uses therefor |
| CN114875144B (zh) * | 2022-04-02 | 2026-04-17 | 及智(苏州)医学技术有限公司 | 用于评估肿瘤ibc疗法的疗效的生物标志物、系统、方法及试剂盒 |
| WO2023224913A1 (en) * | 2022-05-16 | 2023-11-23 | Cz Biohub Sf, Llc | Integrated host-microbe metagenomics of cell-free nucleic acid for sepsis diagnosis |
| EP4471784A1 (fr) * | 2023-05-31 | 2024-12-04 | Biomérieux | Procede et systeme de typage probabiliste de souches microbiennes |
| EP4471785A1 (fr) * | 2023-05-31 | 2024-12-04 | Biomérieux | Procede et systeme de typage probabiliste de souches microbiennes |
| WO2025257393A1 (en) * | 2024-06-14 | 2025-12-18 | Roche Diagnostics Gmbh | Method and system for improving biomarker based disease assessments |
| CN119842884B (zh) * | 2025-01-09 | 2025-09-19 | 湖北文理学院 | Tm9sf1在制备用于监测脓毒症病程的试剂中的应用 |
| CN120405150B (zh) * | 2025-07-01 | 2025-11-18 | 南昌大学第一附属医院 | Itga6在制备脓毒症诊断及病情监测试剂或试剂盒中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI980488A7 (fi) * | 1998-03-04 | 1999-09-05 | Arctic Partners Oy Ab | Uusi diagnostinen menetelmä |
| US7622260B2 (en) * | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
| US20070134261A1 (en) | 2001-12-03 | 2007-06-14 | Hancock Robert E | Effectors of innate immunity |
| JP2004041121A (ja) * | 2002-07-12 | 2004-02-12 | Hitachi Ltd | アレルギー解析方法及びシステム |
| WO2004044556A2 (en) | 2002-11-12 | 2004-05-27 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
| US20040096917A1 (en) | 2002-11-12 | 2004-05-20 | Becton, Dickinson And Company | Diagnosis of sepsis or SIRS using biomarker profiles |
| US20080070235A1 (en) | 2003-04-02 | 2008-03-20 | Sirs-Lab Gmbh | Method for Recognizing Acute Generalized Inflammatory Conditions (Sirs), Sepsis, Sepsis-Like Conditions and Systemic Infections |
| EP1639090A4 (en) * | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| JP2007518062A (ja) * | 2003-09-29 | 2007-07-05 | バイオサイト インコーポレイテッド | 敗血症を診断する方法および診断するための組成物 |
| DE102004009952B4 (de) | 2004-03-01 | 2011-06-01 | Sirs-Lab Gmbh | Verfahren zur Erkennung von Sepsis |
| US9164104B2 (en) | 2004-10-06 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
| CA2605143A1 (en) | 2005-04-15 | 2006-10-26 | Becton, Dickinson And Company | Diagnosis of sepsis |
| EP1907858A4 (en) | 2005-06-13 | 2009-04-08 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| DE102005050933A1 (de) | 2005-10-21 | 2007-04-26 | Justus-Liebig-Universität Giessen | Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen |
| US20090297474A1 (en) * | 2005-11-25 | 2009-12-03 | Dermot Kelleher | Method for Detecting or Monitoring Sepsis by Analysing Cytokine mRNA Expression Levels |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| US20070255113A1 (en) | 2006-05-01 | 2007-11-01 | Grimes F R | Methods and apparatus for identifying disease status using biomarkers |
| WO2008021115A2 (en) | 2006-08-14 | 2008-02-21 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
| EP2185728A2 (en) * | 2007-09-07 | 2010-05-19 | Université Libre de Bruxelles | Methods and tools for prognosis of cancer in er- patients |
| US20100285001A1 (en) * | 2007-10-02 | 2010-11-11 | University Of Rochester | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| DE102008000715B9 (de) | 2008-03-17 | 2013-01-17 | Sirs-Lab Gmbh | Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen |
| JP2009229340A (ja) * | 2008-03-25 | 2009-10-08 | Sysmex Corp | 全身性炎症反応症候群の重症度に関する情報を生成する方法及び装置 |
| CA2749601C (en) * | 2009-01-14 | 2020-07-21 | Stephen M. Hewitt | Ratio based biomarkers and methods of use thereof |
| AU2010270313B2 (en) | 2009-07-10 | 2014-05-22 | Transgene Sa | Biomarker for selecting patients and related methods |
| US20110076685A1 (en) | 2009-09-23 | 2011-03-31 | Sirs-Lab Gmbh | Method for in vitro detection and differentiation of pathophysiological conditions |
| US20110312521A1 (en) | 2010-06-17 | 2011-12-22 | Baylor Research Institute | Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases |
| US20140037649A1 (en) | 2010-11-26 | 2014-02-06 | Immunexpress Pty Ltd | Diagnostic and/or screening agents and uses therefor |
| EP2756118A4 (en) | 2011-09-16 | 2015-09-16 | Cepheid | METHOD FOR DETECTING SEPSIS |
| US20150315643A1 (en) | 2012-12-13 | 2015-11-05 | Baylor Research Institute | Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis |
| US10190169B2 (en) | 2013-06-20 | 2019-01-29 | Immunexpress Pty Ltd | Biomarker identification |
| US11047010B2 (en) | 2014-02-06 | 2021-06-29 | Immunexpress Pty Ltd | Biomarker signature method, and apparatus and kits thereof |
-
2015
- 2015-02-06 US US15/117,137 patent/US11047010B2/en active Active
- 2015-02-06 AU AU2015213486A patent/AU2015213486B2/en active Active
- 2015-02-06 DK DK15746053.6T patent/DK3103046T3/da active
- 2015-02-06 WO PCT/AU2015/050043 patent/WO2015117204A1/en not_active Ceased
- 2015-02-06 US US14/616,565 patent/US20150218640A1/en not_active Abandoned
- 2015-02-06 CA CA2930925A patent/CA2930925A1/en not_active Abandoned
- 2015-02-06 CN CN201580007568.9A patent/CN105981026A/zh active Pending
- 2015-02-06 JP JP2016550561A patent/JP2017512304A/ja active Pending
- 2015-02-06 EP EP15746053.6A patent/EP3103046B1/en active Active
- 2015-05-15 US US14/714,188 patent/US10865447B2/en active Active
-
2022
- 2022-02-23 US US17/678,658 patent/US20220325348A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512304A5 (https=) | ||
| Yeri et al. | Evaluation of commercially available small RNASeq library preparation kits using low input RNA | |
| Bender et al. | Quantification of variation and the impact of biomass in targeted 16S rRNA gene sequencing studies | |
| Hoy et al. | Parasite-derived microRNAs in host serum as novel biomarkers of helminth infection | |
| Mick et al. | Upper airway gene expression differentiates COVID-19 from other acute respiratory illnesses and reveals suppression of innate immune responses by SARS-CoV-2 | |
| EP3729439B1 (en) | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression | |
| JP2018514189A5 (https=) | ||
| US20190355438A1 (en) | Inferring selection in white blood cell matched cell-free dna variants and/or in rna variants | |
| JP7060518B2 (ja) | 早産転帰に対する早期リスク評価のための方法及びシステム | |
| HK1257433A1 (zh) | 免疫組庫正常性評估方法及其應用 | |
| JP2018525703A5 (https=) | ||
| JP2022502027A (ja) | 複数のｂｅｓｐｏｋｅスパイクイン混合物を介した、微生物叢の配列処理および示差的存在量分析を検証するための、組成物、システム、装置、および方法 | |
| JP2019535286A (ja) | 乳がん患者の化学治療の有用性を予測する方法 | |
| US12499972B2 (en) | Identifying false positive variants using a significance model | |
| WO2014187884A2 (en) | Mirnas as non-invasive biomarkers for heart failure | |
| CN117587145A (zh) | 免疫年龄预测的生物标志物、方法、系统、介质、电子设备及诊断试剂盒 | |
| CN105779580A (zh) | 评估罹患结肠直肠癌风险的方法及标志物 | |
| CN117587144B (zh) | 一种基于普通转录组测序方法的免疫相关生物标志物、试剂盒和免疫年龄预测模型 | |
| CN119307603A (zh) | 脓毒症凝血相关预后标志基因及其在制备脓毒症预后预测诊断产品中的应用 | |
| CN114566224B (zh) | 一种用于鉴别或区分不同海拔人群的模型及其应用 | |
| CN105177130B (zh) | 用来评估艾滋病人发生免疫重建炎性综合症的标志物 | |
| TWI718474B (zh) | 評估個體罹患泌尿上皮癌之風險的方法及其套組 | |
| CN116064773B (zh) | 一组用于检测血铅诱导儿童智力降低的生物标志物及其应用 | |
| TWI626314B (zh) | 評估罹患大腸直腸癌風險的方法 | |
| US20230175064A1 (en) | Methods and systems for monitoring organ health and disease |